AI And Drug Discovery: How Swiss Pharma Is Racing Ahead

(MENAFN- Swissinfo) Pharmaceutical giants, including Swiss firms Roche and Novartis, are betting big on artificial intelligence to discover new drugs to treat a range of diseases. But there's a long road ahead to bring AI-discovered drugs to patients. This content was published on January 30, 2026 - 08:59

I report on the Swiss pharmaceutical industry and healthcare topics such as access to medicine, biomedical innovation, and the impact of diseases like cancer. I grew up just outside San Francisco and studied international affairs with a focus on development economics and healthcare policy. Prior to joining SWI swissinfo in 2018, I was a freelance journalist and a researcher on business and human rights.

• More from this aut
• English Departm

I lead diverse teams of distribution specialists and multimedia journalists in creating multilingual content for a range of online platforms. I oversee the strategic development of our podcast and video products, driving innovative content creation and audience engagement. After training as a broadcast journalist at City University of London, I worked in production and on-air as a journalist or contributor for a range of prime-time TV and radio programmes at top-tier broadcasters including the BBC, NPR, Deutsche Welle, and various commercial networks.

• More from this aut
• Multime

My work is focused on making videos and podcasts about science and technology topics. I specialize in developing explainatory video formats for mobile viewing, mixing animation and documentary styles. I studied filmmaking and animation at Zurich University of the Arts and began working as a video journalist at SWI swissinfo in 2004. Since then I have specialised in creating different styles of animation for our visual products.

• More from this aut
• Multime

Subscribe to

• Apple PodcastsExternal link
• SpotifyExternal link
• Amazon MusicExternal link
• Podcast IndexExternal link
• OvercastExternal link
• YouTubeExternal link
• iHeartRadioExternal link
• PandoraExternal link
• Podcast AddictExternal link
• CastroExternal link
• CastboxExternal link
• PodchaserExternal link
• Pocket CastsExternal link
• DeezerExternal link
• Listen NotesExternal link
• Player FMExternal link
• GoodpodsExternal link
• True FansExternal link
• Buzzsprout RSS Feed External l

External Content

In this episode of 'The Swiss Connection'External link we're looking at how AI is revolutionising the development of new therapies, and whether it is living up to its promise.

Pharmaceutical labs have been using machine learning to assist drug development for years but until recently there was some reticence to rely too heavily on AI. This mindset has changed with the latest generation of AI models that can analyse and find patterns in vast and disparate datasets and even images. Beyond speeding up drug discovery, AI has the potential to identify and even generate molecules that chemists haven't even dreamed of.

Swissinfo speaks with medicinal chemist Matthias Steger and Gisbert Schneider, who teaches computer-assisted drug design at the Swiss Federal Institute of Technology ETH Zurich, about how AI helped discover a drug candidate for a rare, degenerative eye disease.

Join Jessica Davis Plüss on the new season of 'The Swiss Connection'External link.

Find out more about the 'The Swiss Connection' science podcast and our other Swiss podcasts in English here, on Apple PodcastsExternal link, or SpotifyExternal link.

More More Big Pharma steps up race for AI-discovered drugs

This content was published on May 30, 2024 AI is speeding up drug discovery but bringing an AI-discovered drug to market won't happen overnight.

Read more: Big Pharma steps up race for AI-discovered

MENAFN30012026000210011054ID1110672352